Letter Agreement, dated February 1, 2025, by and between José E. Almeida and the Company

Transition. Your service as Chief Executive Officer of the Company, Chair of the Board and Director will cease on February 3, 2025 (the “Transition Date”), and, concurrently therewith, you will execute the Resignation Letter attached hereto as Annex A, pursuant to which you will voluntarily and irrevocably resign as a director, member or officer of the Company and of each of its subsidiaries (collectively, the “Group”) and as a member of any committee of the Group or any board of directors, board of managers or special subcommittee thereof. On the Transition Date, you will transition into a non-executive officer employee role (“Advisor”) and continue service in such role through October 31, 2025, or, if earlier, upon your death or Disability or termination by the Company for Cause (such date, the “Separation Date”, and such period, the “Advisory Period”). The Company will not terminate the Advisory Period other than as a result of you committing Cause. Your service relationship with the Company will end on the Separation Date. Both you and the Company hereby waive any otherwise existing notice requirements under any previous agreements or arrangements you have with the Company.

Advisory Period Compensation. Subject to your continued service as Advisor and compliance with the Release Requirement (as defined below), while serving as Advisor, you will continue to be eligible to participate in the Company’s health and other benefits and receive salary payable on the Company’s regular payroll schedule based on an annual rate of $650,000 but will not be eligible for any annual incentive plan (MICP) opportunity or long-term incentive awards for your service during 2025. For the avoidance of doubt, you will be eligible for a full-year bonus based on actual corporate performance under the MICP for your service during 2024, and no individualized negative discretion will be applied to your MICP bonus.

Separation Benefits. Subject to your compliance with the Release Requirement (as defined below), the Company shall pay you a lump-sum separation payment equal to two times your annual base salary and annual target bonus as of immediately prior to the Transition Date payable no later than 60 days following the Separation Date.

Equity Awards Treatment. Subject to your continued service as Advisor and compliance with the Release Requirement (as defined below), your equity awards will continue to vest through the Separation Date and remain subject to the terms of the applicable award agreements, the applicable long-term incentive plan and your Offer Letter (including, as applicable, retirement treatment). For the avoidance of doubt, your separation as of the Separation Date for any reason other than for Cause or as a result of your death or Disability shall be deemed a “Qualifying Retirement” under the terms of your outstanding awards under the Company’s 2021 Incentive Plan, which are included in the schedule of your equity holdings which is attached hereto as Exhibit A.

Release Requirement. You (or, in the case of your death, your beneficiaries or estate) agree to execute and cause to become irrevocable the release attached hereto as Annex B within forty-five (45) days after the Transition Date and a supplemental release and general waiver in a substantially similar form that is acceptable to the Company (each, a “Release”) within forty-five (45) days after the Separation Date (the “Release Requirement”).

Restrictive Covenants. You will continue to abide by the restrictive covenants set forth in Section 9 of the CIC Agreement (outside of the context of the CIC Agreement) and all other obligations set forth in any contract or agreement with the Company which contain restrictive covenants related to confidentiality, non-competition, non-solicitation, and intellectual property ownership (including without limitation that certain Agreement Regarding Competition and Protection of Proprietary Interests between you and the Company (the “CPPI”)) (collectively, the “Restrictive Covenants”). The Restrictive Covenants are incorporated herein by reference and shall remain in full force and effect, in each case, subject to and, if applicable, as modified by, the terms and conditions set forth in Annex C. You understand that nothing in this Letter (including Annex C), the CIC Agreement, the CPPI, a Release, or any other agreement between you and the Company, shall in any way limit or prohibit you from engaging in any Protected Activity. “Protected Activity” shall mean filing a charge, complaint, or report with, or otherwise communicating with, cooperating with, providing information to, responding to any inquiries from or participating in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board (“Agencies”), or discussing the terms and conditions of your employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act. You understand that in connection with such Protected Activity, you are permitted to disclose documents or other information to Agencies as permitted by law, and without giving notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, you agree to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute confidential information of the Company to any parties other than the relevant Agencies. You further understand that “Protected Activity” does not include the disclosure of any Company attorney-client privileged communications, and that any such disclosure without the Company’s written consent shall constitute a material breach of this Letter.

Withholding; Section 409A. All payments to you from the Company will continue to be subject to tax and other withholding and deductions, as required or permitted by applicable law and Company policies. All payments and awards to you from the Company will continue to be subject to any clawback policy of the Company to the extent applicable.

Indemnification. The Company shall indemnify you for your actions or inactions through and during the Advisory Period and shall provide continued D&O coverage for your actions or inactions on or prior to the Transition Date.

Legal Fees. The Company shall reimburse you up to thirty-five thousand dollars ($35,000) for the legal fees reasonably incurred by you in connection with the negotiation and documentation of this Letter; provided that, upon request by the Company, you provide the Company with reasonable documentation of such fees.

Entire Agreement. Except as expressly provided herein or in the Release, this Letter, together with the Release, supersedes any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof which have been made by either party, including, without limitation, your Offer Letter and your CIC Agreement.

Counterparts. This Letter may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

Choice of Law; Disputes. The validity, interpretation, construction and performance of this Letter shall be governed by the laws of the State of Illinois.

Reporting and Messaging. The Company agrees to provide you with a reasonable opportunity to review, and will consider any reasonable comments on, the press release and internal communications regarding your transition, prior to filing or other public disclosure or dissemination thereof.

/s/ José E. Almeida